Bladder cancer accounts for approximately 90% to 95% of all new cases of urothelial cancer, with more than 80,000 new cases diagnosed in the United States every year.1,2 Bladder cancers are described as muscle invasive or non-muscle invasive based on whether they have invaded into the wall of the bladder.
The current standard of care for treating NMIBC patients is transurethral resection of bladder tumor (TURBT), followed by adjuvant chemotherapy or, in certain cases, immunotherapy at the discretion of the treating physician.3,4
TURBT is a surgical procedure performed under anesthesia in a hospital setting using a special scope called a resectoscope.5
Recurrence of disease is common after TURBT—30%-40% at 1 year and up to 70% at 5 years—and it is not unusual for patients to require multiple surgical procedures to control NMIBC over a lifetime, making bladder cancer one of the costliest cancer to treat in the United States.
There are currently no drugs approved by the US Food & Drug Administration (FDA) for first-line treatment of NMIBC—the 3 drugs approved for NMIBC are all used for adjuvant treatment.
UGN-102 (mitomycin gel) is an investigational formulation that utilizes our innovative technology, RTGel™ reverse-thermal hydrogel, for the treatment of low-grade NMIBC.
Administered locally via standard catheters, UGN-102 is designed to fill and conform to the anatomy of the bladder and dwell for a period of several hours before being excreted via normal urine flow.